Search

Your search keyword '"Cecchi, Cristina"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Cecchi, Cristina" Remove constraint Author: "Cecchi, Cristina" Database MEDLINE Remove constraint Database: MEDLINE
84 results on '"Cecchi, Cristina"'

Search Results

1. Editorial: Promising therapeutic strategies for Alzheimer's disease: a focus on amyloid-β targeting.

2. Structure-Toxicity Relationship in Intermediate Fibrils from α-Synuclein Condensates.

4. A single-domain antibody detects and neutralises toxic Aβ 42 oligomers in the Alzheimer's disease CSF.

5. An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature.

6. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.

7. Quantitative Attribution of the Protective Effects of Aminosterols against Protein Aggregates to Their Chemical Structures and Ability to Modulate Biological Membranes.

8. The Toxicity of Protein Aggregates: New Insights into the Mechanisms.

9. APP and Bace1: Differential effect of cholesterol enrichment on processing and plasma membrane mobility.

10. Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience.

11. Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid-β oligomers through endocytic internalization of NMDA receptors.

12. Biophysical characterization of full-length TAR DNA-binding protein (TDP-43) phase separation.

13. Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases.

14. Misfolded protein oligomers induce an increase of intracellular Ca 2+ causing an escalation of reactive oxidative species.

15. A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43.

16. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.

18. Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-β and α-Synuclein and Suppress the Toxicity of Their Oligomers.

19. Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy.

20. Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis.

21. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells.

22. Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors.

23. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.

24. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.

25. Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism.

26. Nanoscopic insights into the surface conformation of neurotoxic amyloid β oligomers.

27. Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies.

28. Identification of Novel 1,3,5-Triphenylbenzene Derivative Compounds as Inhibitors of Hen Lysozyme Amyloid Fibril Formation.

29. Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases.

30. The Toxicity of Misfolded Protein Oligomers Is Independent of Their Secondary Structure.

31. Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies.

32. The acute myeloid leukemia-associated Nucleophosmin 1 gene mutations dictate amyloidogenicity of the C-terminal domain.

33. Capturing Aβ42 aggregation in the cell.

34. Trodusquemine enhances Aβ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes.

35. Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.

36. Toxic HypF-N Oligomers Selectively Bind the Plasma Membrane to Impair Cell Adhesion Capability.

37. Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers.

38. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy.

39. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.

40. Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload.

41. Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases.

42. Destabilisation, aggregation, toxicity and cytosolic mislocalisation of nucleophosmin regions associated with acute myeloid leukemia.

43. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.

44. Interaction of toxic and non-toxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy.

45. Effect of molecular chaperones on aberrant protein oligomers in vitro: super-versus sub-stoichiometric chaperone concentrations.

46. Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct Aβ1-42 oligomers.

47. Nucleophosmin contains amyloidogenic regions that are able to form toxic aggregates under physiological conditions.

48. Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity.

49. S-linolenoyl glutathione intake extends life-span and stress resistance via Sir-2.1 upregulation in Caenorhabditis elegans.

50. A complex equilibrium among partially unfolded conformations in monomeric transthyretin.

Catalog

Books, media, physical & digital resources